FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Deutsche Boerse AG 03:20:58 27/06/2024 pm IST | ||
| 87.84 EUR | +3.00% |
|
| Current month | +85.39% | ||
| 1 month | +62.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 87.84 | +3.00% |
| 26/24/26 | 85.28 | -14.51% |
| 25/24/25 | 99.76 | +29.14% |
| 24/24/24 | 77.25 | -3.07% |
| 21/24/21 | 79.7 | +5.52% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 03:20 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SQ70TH |
| ISIN | DE000SQ70TH1 |
| Date issued | 17/01/2023 |
| Strike | 935.4 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 112.4 € |
|---|---|
| Lowest since issue | 4.22 € |
| Spread | 1.35 € |
| Spread % | 1.54% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
937.9
DKK
Spread / Average Target
-6.86%
- Stock Market
- Certificates
- Certificat
